On Monday, H.C. Wainwright adjusted its outlook on Alector Inc . (NASDAQ:ALEC) shares, reducing the price target significantly to $7.00 from the previous $35.00, while still maintaining a Buy rating on the stock. The decision followed Alector's announcement that its Phase 2 INVOKE-2 trial for the TREM2 antibody, AL002, aimed at treating Alzheimer's disease patients, failed to meet its primary endpoint.
The INVOKE-2 trial's inability to demonstrate significant differences in Alzheimer's disease biomarkers, such as amyloid plaque levels, has led to the conclusion that the TREM2 biology might be more intricate in humans compared to animal models.
The revelation has resulted in the discontinuation of the AL002 program. The unexpected outcomes, particularly the instances of ARIA not correlating with plaque removal as anticipated, have presented a surprising twist to the Alzheimer's research community.
Despite this setback, Alector's pipeline still holds promise with its PGRN program, specifically latozinemab (AL001), which is expected to produce results in late 2025 to early 2026. The program focuses on a more direct causal connection with frontotemporal dementia due to granulin mutations (FTD-GRN).
Alector is also advancing five early-stage programs based on their ABC transport technology, targeting genetically validated Parkinson's disease markers such as GPNMB and GCase.
The anticipation of early proof-of-concept trials for these programs suggests potential for future collaborations, which could positively impact Alector's valuation. In light of the recent trial outcomes, H.C. Wainwright has revised their valuation model, removing AL002 and updating operating expense projections, leading to the new price target of $7.
In other recent news, Alector Inc. halted its Alzheimer's trial after missing the primary endpoint. The company has also secured a $50 million credit facility from Hercules Capital (NYSE:HTGC) Inc. to support ongoing research and development efforts.
Alector's second-quarter results led to Mizuho (NYSE:MFG) Securities and TD Cowen maintaining an Outperform and Buy rating respectively. However, Goldman Sachs reaffirmed its Sell rating, focusing on the upcoming Phase 2 results from the INVOKE-2 study.
Alector's governance saw shareholders elect Louis J. Lavigne, Jr., Richard H. Scheller, Ph.D., and Mark Altmeyer as Class III directors, while Ernst & Young LLP was ratified as the independent accounting firm.
The company reported having $457.2 million in cash, cash equivalents, and investments as of September 30, 2024, projecting a financial runway through 2026. These are among the recent developments shaping the course of the company.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on Alector's financial situation following the disappointing INVOKE-2 trial results. The company's market capitalization stands at $387.81 million, reflecting the market's reassessment of its value. Alector's revenue for the last twelve months as of Q3 2023 was $61.51 million, with a concerning revenue decline of 36.14% over the same period.
InvestingPro Tips highlight some critical aspects of Alector's current position. The company is quickly burning through cash, which is particularly concerning given the recent setback in its Alzheimer's program. This cash burn rate may accelerate as Alector pivots to focus on its other pipeline candidates. On a positive note, Alector holds more cash than debt on its balance sheet, providing some financial flexibility as it navigates this challenging period.
Analysts have revised their earnings expectations downward for the upcoming period, aligning with H.C. Wainwright's more cautious outlook. This adjustment is reflected in the expectation that Alector will not be profitable this year, underscoring the importance of its remaining pipeline programs and potential future collaborations.
For investors seeking a more comprehensive analysis, InvestingPro offers 11 additional tips that could provide valuable insights into Alector's financial health and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.